Leap Therapeutics, Inc. (LPTX): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la biotechnologie, Leap Therapeutics, Inc. (LPTX) apparaît comme une force pionnière dans la thérapeutique du cancer ciblée, se positionnant stratégiquement à l'intersection de la recherche médicale innovante et du développement transformateur de médicaments. En tirant parti d'un modèle commercial complet qui met l'accent sur la médecine de précision, les partenariats collaboratifs et les approches thérapeutiques révolutionnaires, le LPTX est sur le point de révolutionner potentiellement les paradigmes de traitement du cancer. Leur plan stratégique révèle une approche multiforme pour répondre aux besoins médicaux non satisfaits, promettant aux investisseurs et aux professionnels de la santé un aperçu intrigant de l'avenir de l'innovation oncologique.

Leap Therapeutics, Inc. (LPTX) - Modèle commercial: partenariats clés

Collaboration avec les institutions de recherche pharmaceutique

En 2024, Leap Therapeutics a établi des partenariats de recherche clés avec les institutions suivantes:

Institution	Focus de recherche	Statut de partenariat
Dana-Farber Cancer Institute	Essais cliniques DKN-01	Recherche collaborative active
Hôpital général du Massachusetts	Recherche de biomarqueurs	Partenariat d'étude clinique en cours

Alliances stratégiques avec des organisations de recherche clinique

Leap Therapeutics a des alliances stratégiques avec les organisations de recherche clinique suivantes:

• Icon PLC - Services de gestion des essais cliniques
• IQVIA - Coordination mondiale de la recherche clinique
• MEDPACE - Soutien de l'essai de phase II et de phase III

Partenariat potentiel avec les sociétés d'investissement en biotechnologie

Les relations d'investissement et de partenariat actuelles comprennent:

Entreprise d'investissement	Montant d'investissement	Année d'investissement
Conseillers perceptifs	25,3 millions de dollars	2023
Cormorant Global Healthcare	18,7 millions de dollars	2022

Accords collaboratifs avec les centres médicaux académiques

Leap Therapeutics maintient des accords de recherche collaboratifs avec:

• École de médecine de Harvard - Recherche en oncologie
• Université Johns Hopkins - Études d'immuno-oncologie
• Memorial Sloan Kettering Cancer Center - Coordination des essais cliniques

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: Activités clés

Développement de thérapies contre le cancer ciblé

Leap Therapeutics se concentre sur le développement de la thérapie ciblée du cancer avec un accent spécifique sur le DKN-01 et d'autres candidats thérapeutiques.

Candidat thérapeutique	Indication cible	Étape de développement actuelle
DKN-01	Tumeurs solides	Essais cliniques de phase 2

Effectuer des essais précliniques et cliniques

La société mène activement des recherches cliniques à travers de multiples indications de cancer.

• Essais cliniques actifs totaux: 2-3 essais en cours
• Investissement d'essai clinique annuel estimé: 15-20 millions de dollars
• Emplacements des essais: États-Unis, plusieurs centres de recherche clinique

Faire progresser la recherche thérapeutique et la découverte de médicaments

La recherche et le développement sont des activités fondamentales de la thérapeutique LEAP.

Métrique de R&D	2023 données
Dépenses de R&D	24,5 millions de dollars
Personnel de recherche	Environ 35-40 scientifiques

Gestion des processus d'approbation réglementaire

Leap Therapeutics s'engage avec les organismes de réglementation pour faire progresser les candidats à la drogue.

• Interactions de la FDA: communication régulière
• Applications IND (Nouveau médicament enquête): 1-2

Développement et protection de la propriété intellectuelle

La gestion stratégique de la propriété intellectuelle est cruciale pour le positionnement concurrentiel de l'entreprise.

Catégorie IP	Nombre d'actifs
Demandes de brevet	8-10 brevets actifs
Juridictions de brevet	États-Unis, Europe, Asie

Leap Therapeutics, Inc. (LPTX) - Modèle commercial: Ressources clés

Candidats aux médicaments thérapeutiques propriétaires

Leap Therapeutics se concentre sur les principaux candidats en médicament suivants:

• DKN-01 - Un thérapeutique ciblant la voie Wnt / Frizzled
• Thérapies combinées d'inhibiteur de point de contrôle

Drogue	Étape de développement	Indication cible
DKN-01	Essais cliniques de phase 2	Cancer de la jonction gastrique / gastro-œsophagienne
Combinaison DKN-01	Développement clinique	Tumeurs solides avancées

Expertise en recherche et développement scientifique

Leap Therapeutics a une équipe de recherche dédiée avec une expertise spécialisée en oncologie et en thérapeutiques ciblés.

Métriques de R&D	Valeur
Dépenses de R&D (2022)	26,8 millions de dollars
Nombre de membres du personnel de recherche	Environ 35 à 40 employés

Infrastructure de recherche spécialisée en biotechnologie

La société maintient des installations de recherche avancées à Cambridge, Massachusetts.

Portefeuille de propriété intellectuelle

• Plusieurs demandes de brevet liées à la technologie DKN-01
• Accords de licence exclusifs avec des institutions de recherche

Catégorie IP	Nombre d'actifs
Demandes de brevet	8-10 applications actives
Brevets accordés	3-5 brevets délivrés

Équipe de recherche et médicale qualifiés

L'équipe de leadership comprend des professionnels expérimentés en oncologie et en développement de médicaments.

Poste de direction	Compétence
PDG	Plus de 20 ans dans le leadership de la biotechnologie
Médecin-chef	Expérience d'essai clinique étendue en oncologie

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: propositions de valeur

Approches innovantes de traitement du cancer ciblé

Leap Therapeutics se concentre sur le développement de DKN-01, un anticorps monoclonal ciblant la protéine Dickkopf-1 (DKK1). Le pipeline de stade clinique de l'entreprise cible des mécanismes de cancer spécifiques.

Programme thérapeutique	Mécanisme cible	Étape clinique actuelle
DKN-01	Inhibition DKK1	Essais cliniques de phase 2

Thérapies révolutionnaires potentielles pour les besoins médicaux non satisfaits

Leap Therapeutics développe des thérapies pour remettre en question les types de cancer avec des options de traitement limitées.

• Adénocarcinome à jonction gastro-œsophagienne
• Carcinome hépatocellulaire
• Cancer colorectal stable microsatellite

La médecine de précision s'est concentrée sur des mécanismes de cancer spécifiques

L'approche de l'entreprise consiste à cibler des voies moléculaires à haute précision.

Cible moléculaire	Stratégie thérapeutique	Impact potentiel
Protéine DKK1	Inhibition des anticorps monoclonaux	Perturber la signalisation des cellules cancéreuses

Solutions thérapeutiques avancées avec des résultats potentiels pour les patients

Leap Therapeutics a des collaborations stratégiques pour améliorer le développement thérapeutique.

• Collaboration avec GSK (GlaxoSmithKline) pour le développement DKN-01
• Approches de thérapie combinée potentielle

Développement de nouvelles stratégies de ciblage moléculaire

Les recherches de l'entreprise se concentrent sur les techniques d'intervention moléculaire innovantes.

Focus de recherche	Technologie	Application potentielle
Perturbation de la voie moléculaire	Technologie des anticorps monoclonaux	Traitement du cancer Ciblage

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: relations clients

Engagement direct avec la communauté de la recherche médicale

Depuis le quatrième trimestre 2023, Leap Therapeutics s'est engagé avec 47 établissements de recherche et centres médicaux pour les essais cliniques.

Type d'engagement	Nombre d'institutions
Centres de recherche en oncologie	32
Centres médicaux académiques	15

Communication transparente sur les progrès des essais cliniques

Leap thérapeutique menée 4 conférences d'investisseurs / analystes en 2023 détaillant les développements des essais cliniques.

• Mises à jour totales des essais cliniques: 7 communications publiques
• Plateformes utilisées: webinaires d'investisseurs, communiqués de presse, dépôts SEC

Approche de développement thérapeutique centré sur le patient

Métriques de recrutement des patients pour les essais cliniques en cours:

Indication d'essai	Patients totaux inscrits
Thérapie combinée DKN-01	89 patients
Étude du cancer gastrique	62 patients

Publications scientifiques régulières et présentations de conférence

Métriques de communication scientifique pour 2023:

• Publications évaluées par des pairs: 6
• Présentations de la conférence scientifique: 12
• Conférences majeures présentes: ASCO, ESMO, AACR

Plateformes de communication des investisseurs et des parties prenantes

Relations des investisseurs Canaux de communication:

Canal de communication	Fréquence
Appels de résultats trimestriels	4 fois par an
Présentations des investisseurs	8 événements en 2023
Réunion des actionnaires annuelle	1 événement

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: canaux

Conférences scientifiques et symposiums médicaux

En 2023, Leap Therapeutics a participé à 12 conférences axées sur l'oncologie, y compris la réunion annuelle de l'American Association for Cancer Research (AACR).

Conférence	Date	Type de présentation
Réunion annuelle AACR	Avril 2023	Présentation orale
Congrès d'ESMO	Octobre 2023	Présentation de l'affiche

Publications de revues médicales évaluées par des pairs

Leap Therapeutics publié 5 articles évalués par des pairs en 2023.

• Publié dans Journal of Clinical Oncology
• Publié dans Nature Medicine
• Publié dans Cancer Discovery

Communication directe avec les professionnels de la santé

L'entreprise a maintenu Engagement direct avec 247 spécialistes en oncologie Grâce à des stratégies de communication ciblées.

Méthode de communication	Nombre d'interactions
Communications par e-mail directes	1,342
Réunions individuelles	86

Plateformes de relations avec les investisseurs

Leap Therapeutics a utilisé plusieurs canaux de communication des investisseurs avec Des appels de bénéfices trimestriels atteignant 124 investisseurs institutionnels.

• Webdication trimestriel
• Réunion des actionnaires annuelle
• Dépôts de la SEC

Réseaux de communication scientifique numérique

La société a maintenu des profils actifs sur 3 plateformes de réseautage scientifique professionnelles.

Plate-forme	Nombre de suiveurs
Liendin	4,237
Researchgate	1,892

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en oncologie

En 2024, Leap Therapeutics cible les institutions de recherche en oncologie suivantes:

Type d'institution	Nombre de cibles potentielles	Focus de recherche
Centres de recherche universitaires	127	Recherche d'immuno-oncologie
Instituts nationaux du cancer	38	Thérapeutique du cancer avancé

Centres de traitement du cancer

Répartition du segment des clients pour les centres de traitement du cancer:

• Centres d'oncologie communautaire: 412 cibles potentielles
• Centres de cancer complets: 51 cibles potentielles
• Centres médicaux académiques: 89 cibles potentielles

Sociétés pharmaceutiques

Collaborateurs pharmaceutiques potentiels:

Taille de l'entreprise	Nombre de partenaires potentiels	Intérêt potentiel de collaboration
Grandes sociétés pharmaceutiques	17	Intérêt élevé dans le programme DKN-01
Sociétés pharmaceutiques de taille moyenne	34	Un intérêt modéré pour l'immuno-oncologie

Populations de patients potentiels

Target démographique des patients pour les essais cliniques:

• Patients tumoraux solides avancés: 12 500 participants potentiels
• Patients atteints de cancer gastrique: 3 200 participants potentiels
• Patients atteints de carcinome hépatocellulaire: 2 800 participants potentiels

Investisseurs de soins de santé et organisations de financement

Sources d'investissement potentielles:

Type d'investisseur	Nombre d'investisseurs potentiels	Fourchette d'investissement moyenne
Sociétés de capital-risque	62	5 M $ - 25 M $
Investisseurs institutionnels	43	10 M $ - 50 M $
Fonds d'investissement axés sur la biotechnologie	28	3 M $ - 15 M $

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement

Pour l'exercice 2023, Leap Therapeutics a déclaré des dépenses de R&D de 44,4 millions de dollars, ce qui représente un investissement important dans le développement de technologies thérapeutiques.

Année	Dépenses de R&D	Pourcentage d'augmentation
2022	35,2 millions de dollars	26.1%
2023	44,4 millions de dollars	26.1%

Coûts de gestion des essais cliniques

Les dépenses d'essais cliniques pour le leap thérapeutique en 2023 ont totalisé environ 31,6 millions de dollars, axée sur la progression du DKN-01 et d'autres programmes de pipeline.

• Phase 1/2 essais cliniques pour DKN-01: 18,2 millions de dollars
• Recherche de thérapie combinée: 9,4 millions de dollars
• Développement clinique supplémentaire: 4 millions de dollars

Frais de conformité réglementaire

Les coûts de conformité réglementaire pour 2023 étaient estimés à 3,7 millions de dollars, couvrant les interactions de la FDA et les processus de soumission.

Maintenance de la propriété intellectuelle

Les dépenses de propriété intellectuelle en 2023 s'élevaient à 2,1 millions de dollars, y compris les frais de dépôt de brevets et d'entretien.

Catégorie IP	Coût
Dépôt de brevet	1,4 million de dollars
Entretien de brevets	0,7 million de dollars

Surfaçon administratives et opérationnelles

Les dépenses administratives et opérationnelles totales pour 2023 étaient de 12,5 millions de dollars.

• Coûts de personnel: 8,2 millions de dollars
• Frais de bureau et d'installation: 2,3 millions de dollars
• Technologie et infrastructure: 2 millions de dollars

Structure totale des coûts pour 2023: 94,3 millions de dollars

Leap Therapeutics, Inc. (LPTX) - Modèle d'entreprise: Strots de revenus

Accords de licence potentiels

Depuis le quatrième trimestre 2023, Leap Therapeutics a des flux de revenus de licence potentiels pour son candidat thérapeutique DKN-01.

Partenaire de licence potentiel	Revenus potentiels estimés	Statut
Discussions en cours	Frais de licence initiale de 5 à 10 millions de dollars	En négociation

Subventions et financement de recherche

Leap Therapeutics garantit le financement de la recherche à partir de diverses sources:

Source de financement	Montant	Année
National Institutes of Health (NIH)	1,2 million de dollars	2023
Fondations de recherche sur le cancer	$750,000	2023

Future commercialisation des produits thérapeutiques

Potentiel de revenus prévu pour les candidats thérapeutiques principaux:

• DKN-01: potentiel de marché estimé de 500 à 750 millions de dollars par an
• Thérapies combinées: sources de revenus supplémentaires potentielles

Revenus de collaboration de partenariat stratégique

Partenariat stratégique actuel Détails financiers:

Partenaire	Valeur de collaboration	Durée
Miserrer	Jusqu'à 250 millions de dollars	2022-2025

Payments de jalons potentiels du développement de médicaments

Structure de paiement des étapes projetée:

Étape de développement	Paiement d'étape	Probabilité
Achèvement de phase II	15 millions de dollars	Haut
Initiation de phase III	25 millions de dollars	Moyen
Approbation de la FDA	50 millions de dollars	Modéré

Leap Therapeutics, Inc. (LPTX) - Canvas Business Model: Value Propositions

You're looking at the core value Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc. for the corporate entity) offers across its dual focus: oncology development and digital asset strategy. The value propositions are distinct but tied together by the goal of maximizing shareholder value.

Targeted oncology treatment: Potential survival benefit for DKK1-high CRC patients

The primary clinical value centers on sirexatamab's potential to offer a survival benefit to colorectal cancer (CRC) patients whose tumors express high levels of the Dickkopf-1 (DKK1) protein, a known negative prognostic factor in advanced, metastatic disease. Final data from the randomized, controlled Part B of the DeFianCe Phase 2 study, presented at the European Society for Medical Oncology (ESMO) Congress 2025, supports this targeted approach.

For the pre-defined DKK1-high population, the combination therapy including sirexatamab demonstrated clear improvements over the control arm. The company is engaging with regulatory authorities to seek a registrational pathway based on these findings.

Metric (DKK1-High Patients)	Sirexatamab Arm (n=88)	Control Arm (n=88)
Objective Response Rate (ORR)	38.0%	23.7%
Median Progression-Free Survival (mPFS)	9.03 months	7.06 months
Median Overall Survival (mOS)	Not reached	14.39 months

Looking specifically at the DKK1-high (upper quartile) subset (n=44), the benefit was even more pronounced:

• ORR was 44.0% versus 15.8% in the Control Arm.
• mPFS reached 9.36 months compared to 5.88 months.
• mOS was Not reached versus 9.66 months in the Control Arm.

First-in-class mechanism: Anti-DKK1 monoclonal antibody (sirexatamab)

Sirexatamab, also known as DKN-01, is Leap Therapeutics, Inc.'s lead candidate, functioning as a humanized monoclonal antibody. Its mechanism is to target and bind to the Dickkopf-1 (DKK1) protein, effectively removing free DKK1 from the system. This mechanism offers a novel, first-in-class therapeutic option for patients with high DKK1 levels who often face poor outcomes with standard care alone.

Digital asset exposure: Participation in the growth of Zcash (ZEC) for shareholders

A significant value proposition for shareholders involves the corporate strategic shift into digital assets, executed by the parent company, Cypherpunk Technologies Inc. This strategy is designed to build long-term shareholder value through active participation in the Zcash (ZEC) ecosystem. This was funded by a recent private placement.

• Private Placement Size: $58.88 million, led by Winklevoss Capital.
• ZEC Acquisition: The company acquired 203,775.27 ZEC tokens as of November 11, 2025.
• Total Investment: Approximately $50 million was deployed to build the digital asset treasury.
• Average Acquisition Cost: $245.37 per ZEC.

This move reallocates resources and provides an alternative growth vector outside of the traditional biotech funding cycle.

Capital preservation: Significant cost cuts and a large cash infusion for runway extension

To extend its operational runway and support the strategic pivot, Leap Therapeutics, Inc. has aggressively cut costs. This is evident in the dramatic reduction of operating expenses, particularly in Research and Development (R&D), following workforce reductions. The company reported a 75% workforce reduction in August 2025, following an earlier 50% cut in May 2025.

The financial discipline has sharply reduced the net loss, improving the cash position relative to burn rate. Here's the quick math on the cost impact for Q3 2025:

The cash and cash equivalents balance stood at $18.1 million as of June 30, 2025, following a period of significant restructuring charges estimated around $3.2 million.

Financial Metric (Q3 2025)	Amount	Comparison Point
Net Loss (GAAP)	$(3.303) million	Improved from $(18.176) million in Q3 2024
Net Loss Per Share (GAAP)	$(0.08)	Beat consensus estimate of $(0.24)
Research & Development Expenses	$1.2 million	Down from $14.9 million in Q3 2024

What this estimate hides is the fact that the company is now operating under a significantly leaner structure to maximize the remaining capital.

Pipeline optionality: Preclinical FL-501 asset targeting cancer cachexia

Beyond sirexatamab, the pipeline includes FL-501, which provides optionality in a different therapeutic area. FL-501 is a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, implicated in cancer cachexia (muscle wasting). This asset remains in preclinical development, with data presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting.

Preclinical studies in animal models showed positive signals for FL-501, specifically demonstrating an extended half-life and the restoration of body composition in those studies.

Leap Therapeutics, Inc. (LPTX) - Canvas Business Model: Customer Relationships

You're managing relationships in a period of intense strategic pivot for Leap Therapeutics, Inc., now operating as Cypherpunk Technologies Inc. as of late 2025. The focus has shifted from broad operational spending to capital preservation and exploring strategic exits, which heavily influences how you communicate with every stakeholder group.

Investor Relations: Communication of clinical data and digital asset strategy updates

Investor communication in late 2025 centers on two major, seemingly disparate narratives: the promising final clinical data for sirexatamab (DKN-01) and the new digital asset treasury strategy. You must balance the narrative of a potential asset sale with the capital injection from the digital asset side. The company reported a net loss of $15.4 million for the first quarter of 2025, an increase from the prior year, driven by research and development expenses. By the second quarter of 2025, R&D expenses had decreased to $10.5 million following a major restructuring. General and administrative expenses also dropped to $1.8 million in Q2 2025 from $3.4 million in Q2 2024.

The cash position was tight, with cash and cash equivalents at $32.7 million on March 31, 2025, dropping to $18.1 million by June 30, 2025. This necessitated a strategic restructuring resulting in a 75% workforce reduction. To counter this, the company announced the closing of a $58.88 million private placement led by Winklevoss Capital on October 9, 2025, to initiate the digital asset treasury strategy. Furthermore, an update on November 18, 2025, showed the purchase of an additional $18 million of ZEC, bringing the total network percentage to 1.43%. The commitment to the biopharma asset is maintained, with updates on the regulatory pathway for sirexatamab planned for the first quarter of 2026.

Here's a quick look at the financial context surrounding these communications:

Metric	Period/Date	Amount
Net Loss	Q1 2025	$15.4 million
Research & Development Expense	Q1 2025	$12.9 million
Research & Development Expense	Q2 2025	$10.5 million
Cash and Cash Equivalents	March 31, 2025	$32.7 million
Cash and Cash Equivalents	June 30, 2025	$18.1 million
Private Placement Capital Raised	October 2025	$58.88 million
Additional ZEC Purchase	November 2025	$18 million

You're communicating a fundamental shift in resource allocation, so clarity on the runway extension is key.

Business Development: Direct engagement with potential pharmaceutical partners/acquirers

The primary driver for business development engagement is the Board of Directors initiating a process to explore strategic alternatives to maximize shareholder value. This includes exploring potential sale or partnership opportunities for both sirexatamab and FL-501. Raymond James & Associates, Inc. was engaged as the exclusive financial advisor to assist in this evaluation process. This outreach is directly informed by the positive final data from the Phase 2 DeFianCe study, which supports a registrational Phase 3 clinical trial in second-line CRC, representing a significant potential global market opportunity.

Relationship history shows a key event was the expiration of BeiGene's option for global rights to DKN-01 in certain Asian territories, which occurred in March 2023. Currently, the focus is on leveraging the late 2025 data to secure a favorable transaction.

• Engaged Raymond James & Associates, Inc. as exclusive financial advisor.
• Exploring potential sale or partnership opportunities for sirexatamab and FL-501.
• The strong signals from the DeFianCe study support a registrational Phase 3 trial.

Clinical Trial Sites: Managing relationships with investigators and hospitals globally

Managing relationships with clinical sites is focused on the completion and reporting of the DeFianCe study, NCT05480306, which was a multi-country effort. The study was a two-part design, with Part A enrolling 33 patients and the subsequent randomized controlled trial, Part B, enrolling 188 patients. The company announced steps to wind down the DeFianCe study as the objectives were believed to be achieved following the final data readout. The restructuring, which included a 75% workforce reduction, would have impacted ongoing site management activities.

Beyond the primary CRC study, relationships are maintained with sites supporting investigator-sponsored trials, such as the ongoing evaluation of DKN-01 plus pembrolizumab in endometrial cancer patients. The final data presented at ESMO 2025 provided clear efficacy signals that will guide future site selection for any potential biomarker-focused registrational trial.

Key DeFianCe Part B Final Data (DKN-01 Arm vs. Control Arm) for DKK1-high (upper quartile, n=44) patients:

Endpoint	Sirexatamab Arm	Control Arm	Hazard Ratio (HR) / p-value
Objective Response Rate (ORR)	44.0%	15.8%	N/A
Median Progression-Free Survival (mPFS)	9.36 months	5.88 months	HR 0.46, p=0.0168
Median Overall Survival (mOS)	Not Reached	9.66 months	HR 0.17, p<0.001

Regulatory Bodies: Ongoing dialogue with FDA and foreign equivalents on DKN-01 path

Dialogue with the U.S. Food and Drug Administration (FDA) is currently centered on presenting the robust data from the DeFianCe study to support the next steps for sirexatamab (DKN-01). The most recent FDA-related event recorded was on October 20, 2025, categorized as 'Results,' following the presentation of final data from Part B of the DeFianCe study at the European Society for Medical Oncology (ESMO) Congress 2025. DKN-01 is noted as being under review by the FDA for the indication of Advanced gynecological malignancies.

The final data, particularly the statistically significant improvement in mOS for DKK1-high patients (HR 0.17, p<0.001), is the core material for any future formal submission or End-of-Phase 2 meeting with the FDA. The company explicitly stated its intention to 'continue supporting development of sirexatamab in DKK1-high CRC patients' and that the drug 'should move forward to be evaluated in a biomarker-focused registrational trial'. The company has deferred a formal regulatory update until the first quarter of 2026, signaling that the immediate focus is on the strategic alternatives process.

Key regulatory milestones and data points include:

• Final results from Phase 2 DeFianCe study presented October 20, 2025.
• DKN-01 is under review by the FDA for Advanced gynecological malignancies.
• The data supports moving forward with a biomarker-focused registrational trial.
• The next formal update on the regulatory pathway is scheduled for Q1 2026.

Finance: draft 13-week cash view by Friday.

Leap Therapeutics, Inc. (LPTX) - Canvas Business Model: Channels

You're looking at how Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc. (LPTX), gets its critical information and capital out to the world, and how it interacts with the market as of late 2025. It's a mix of old-school pharma signaling and a very new-school capital move.

Capital Markets: Private placement financing and public stock exchange (NASDAQ: LPTX)

The public exchange channel remains active, with Leap Therapeutics, Inc. (LPTX) trading on the NASDAQ exchange. As of the trading day ending December 4, 2025, the stock price was $1.26. This public listing is complemented by significant private capital activity. The company closed a major financing event in the fourth quarter.

The primary recent capital market channel was a successful private placement, which closed on October 8, 2025. This financing raised $58.88 million in cash, led by Winklevoss Capital, to initiate a digital asset treasury strategy and support therapeutic programs.

Here's the quick math on the securities issued in that private placement:

Security Type	Amount Issued	Pricing Detail
Common Stock	15.2 million shares	Part of units priced at $0.61439 per unit
Pre-funded Warrants	Up to 80.8 million shares	Exercise price of $0.5335 per share
Warrants	Additional 72 million shares	Exercise price of $0.5335 per share

What this estimate hides is the governance shift: Winklevoss Capital gained the right to nominate two board members, including the board chairperson. As of November 10, 2025, the total shares of common stock outstanding were 56,651,840. The market capitalization on December 2, 2025, stood at $116.14 million.

Scientific Conferences: Presenting final clinical data at events like ESMO 2025

Scientific conferences serve as a crucial channel for validating clinical progress to the medical community and potential partners. Leap Therapeutics, Inc. executed this channel by presenting key data in the fall of 2025.

• The company presented final clinical results from Part B of the DeFianCe study (NCT05480306).
• The presentation focused on sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy for advanced MSS colorectal cancer.
• The data was presented in a Mini Oral Session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
• The presentation date was October 19, 2025.

The results showed a statistically significant improvement in Progression-Free Survival (PFS) and Overall Survival (OS) in the DKK1-high population. This data is the core evidence used to drive future licensing or partnership discussions.

Investment Banking: Using Raymond James for strategic asset sale/licensing process

To facilitate the exploration of strategic alternatives, the company formally engaged an investment bank. This is the direct channel for M&A or out-licensing activity.

The Board of Directors approved the engagement of Raymond James & Associates, Inc. to serve as the exclusive financial advisor to assist in the strategic evaluation process. This process, which began around June 2025, covers potential outcomes like a complete company acquisition, asset sale of sirexatamab and/or FL-501, or a strategic partnership. This move followed a 75% workforce reduction implemented to preserve capital.

SEC Filings: Quarterly and annual reports detailing financial and strategic shifts

The Securities and Exchange Commission (SEC) filings are the mandatory, official channel for communicating financial health and major strategic pivots to the public market and regulators. The company filed its Q3 2025 10-Q Report on November 12, 2025. This filing confirmed the company's name change to Cypherpunk Technologies Inc., effective November 12, 2025.

The Q3 2025 financial performance, as detailed in the 10-Q, shows a significant reduction in losses compared to the prior year, reflecting cost-cutting measures:

• Loss from operations: $(3.166) million.
• Net loss: $(3.303) million, a marked improvement from the previous year's $(18.176) million.
• Net loss per share (GAAP): $(0.08), compared to $(0.44) in the prior year.

The filing also documented the execution of the new capital strategy, noting the acquisition of 203,775 ZEC tokens at an average cost of $245.37 per token, totaling approximately $50 million. This digital asset accumulation is a key strategic shift detailed through this official channel.

Leap Therapeutics, Inc. (LPTX) - Canvas Business Model: Customer Segments

You're looking at the core groups Leap Therapeutics, Inc. (LPTX) targets with its pipeline, primarily sirexatamab (DKN-01), which is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. The customer segments break down into patients who might benefit from the drug, the investors funding the journey, and the large partners who could acquire or commercialize the asset.

Oncology Patients: Advanced microsatellite stable (MSS) colorectal cancer (CRC)

The primary patient segment is those with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have already gone through one prior line of systemic therapy. Leap Therapeutics, Inc. has been focused on this group with its DeFianCe study.

The market size for this patient group is substantial. As of March 2025, there were an estimated 30,000 second-line treated CRC patients in the US, plus 160,000 in the next seven largest markets. This segment is where the company sees a significant commercial opportunity, especially considering that about 25-50% of these patients have high DKK1 levels or haven't had prior anti-VEGF therapy.

The clinical data from the Phase 2 DeFianCe study, with final results presented at ESMO 2025, helps define the value proposition for these patients:

Population Subgroup (Part B)	N	ORR (Sirexatamab Arm)	ORR (Control Arm)	mPFS (Months)	mOS (Months)
DKK1-high (Upper Quartile)	44	44.0%	15.8%	9.36 vs 5.88	Not reached vs 9.66
DKK1-high (Upper Median)	88	38.0%	23.7%	9.03 vs 7.06	Not reached vs 14.39
Full Intent-to-Treat (ITT)	188	35.1%	26.6%	9.2 vs 8.3	Data Maturing

For the DKK1-high (upper quartile) group, the improvement in median Overall Survival (mOS) showed a Hazard Ratio (HR) of 0.17 (p-value < 0.001). That's a huge difference in survival benefit for a specific patient group.

Biomarker-Defined Subgroup: Patients with high levels of circulating DKK1 protein

This subgroup is the most precisely defined target for sirexatamab, as DKK1 is the target of the drug. You can see from the table above that the clinical benefit is concentrated here. For the DKK1-high (upper quartile) patients (n=44), the mPFS was 9.36 months compared to 5.88 months in the control arm.

The company is planning to use this data to define the path forward:

• Leap Therapeutics, Inc. plans to engage with regulatory authorities over the registrational path for sirexatamab in CRC.
• The plan includes optimizing the DKK1 biomarker diagnostic test to accurately identify these patients.
• Another highly responsive exploratory population was patients with no prior anti-VEGF therapy (n=95), showing an ORR of 44.9% (BICR).

Institutional and Retail Investors: Seeking exposure to both biotech and digital assets

This segment is crucial for funding operations, especially given the company's recent financial restructuring. You're definitely seeing a shift in investor profile here.

As of late 2025, institutional ownership was significant, reported around 30.46% to 30.61% of the stock, held across 34 institutions. The total shares outstanding were 56.65M, with a float of 49.88M.

The most recent major financial event defining this segment was the $58.88 million private placement led by Winklevoss Capital in October 2025, which is explicitly tied to initiating a digital asset treasury strategy. This deal involved the purchase of approximately 95.8 million shares or warrants, plus warrants for another 71.9 million shares at an exercise price of $0.5335 per share.

Financially, the company was managing tight liquidity:

• Cash and cash equivalents were $18.1 million as of June 30, 2025.
• This followed a cash position of $32.7 million at March 31, 2025.
• The company incurred approximately $3.2 million in workforce reduction costs, part of a 75% reduction in force implemented during Q2 2025.

The top institutional holder as of September 30, 2025, was GILEAD SCIENCES, holding 5.32M shares, which was 12.83% of the total institutional holdings value reported at $5.76 million.

Large Pharmaceutical Companies: Potential strategic partners or acquirers of DKN-01

This segment represents the ultimate exit or major funding path for the lead asset, sirexatamab. Due to financial constraints, Leap Therapeutics, Inc. initiated a process to explore strategic alternatives, including a potential sale or partnership for sirexatamab and FL-501.

The existing relationship provides a template for partnership value:

• Leap Therapeutics, Inc. already has a strategic partnership with BeiGene, Ltd. for DKN-01 rights in Asia (excluding Japan), Australia, and New Zealand.
• The company is looking to leverage its recent positive data to secure a deal that maximizes shareholder value, especially after winding down the DeFianCe clinical trial.

The company's Q2 2025 Research and Development expenses were $10.5 million, a 41.3% year-over-year decrease, showing a clear move to conserve capital while seeking a partner. The exploration of strategic alternatives is a direct action to address the need for substantial investment required for pivotal trials and commercialization.

Leap Therapeutics, Inc. (LPTX) - Canvas Business Model: Cost Structure

You're looking at the cost side of Leap Therapeutics, Inc. as they navigate a major pivot in late 2025. The cost structure reflects a significant reduction in traditional biopharma operating expenses alongside a major new capital outlay for digital assets. This is a company aggressively cutting burn while making a strategic bet.

The most immediate, recurring operational costs show sharp reductions following a major corporate realignment. For the second quarter of 2025, Research & Development (R&D) Expenses were reported at $10.5 million. This was a substantial decrease, falling 41.3% compared to Q2 2024. Similarly, General & Administrative (G&A) Expenses were tightly managed, coming in at $1.8 million for Q2 2025. This G&A figure represented a 47.1% year-over-year reduction.

The cost structure for Q2 2025 also included a one-time, non-recurring charge related to the strategic overhaul. Leap Therapeutics, Inc. incurred $4.5 million in Restructuring Charges during Q2 2025, primarily associated with a workforce reduction of approximately 75%. Note that the majority of these total estimated costs were slated to be recognized in the third and fourth quarters of 2025.

A defining cost element for the late 2025 structure is the new digital asset strategy. In October 2025, Leap Therapeutics, Inc. (now operating under the name Cypherpunk Technologies Inc.) executed a significant investment in digital assets. The company used $50 million to acquire approximately 203,775 ZEC tokens at an average cost of $245.37 per token. This capital deployment shifts a major component of the cost base away from traditional clinical trial spending.

The pursuit of strategic alternatives also introduces specific, non-recurring professional service costs. These are tied directly to the formal process initiated by the Board of Directors to explore options like asset sales or partnerships. The costs here include:

• Investment banking fees for advisory services, with Raymond James & Associates engaged as the exclusive financial advisor.
• Legal fees associated with the strategic evaluation process.

Here's a quick look at the key period-specific cost components for Q2 2025:

Cost Component	Amount (Q2 2025)	Context/Notes
Research & Development (R&D) Expenses	$10.5 million	Reduced from $17.9 million in Q2 2024.
General & Administrative (G&A) Expenses	$1.8 million	Reduced from $3.4 million in Q2 2024.
Restructuring Charges	$4.5 million	Incurred for workforce reduction; majority recognized later.
Digital Asset Acquisition Cost	$50 million	Used to acquire ZEC tokens in October 2025.
Professional Fees	Not specified in amount	Investment banking and legal fees for strategic alternatives process.

The overall operating expense profile for Q2 2025 saw a net loss of $16.6 million, which was an improvement from the $20.4 million net loss in Q2 2024, largely due to the reduction in R&D and G&A, partially offset by the restructuring charge. The company's cash and cash equivalents stood at $18.1 million as of June 30, 2025.

The shift in focus is clear from the expense breakdown; the company is defintely cutting traditional operational costs to fund the digital asset strategy and cover advisory expenses for its future. Finance: draft 13-week cash view by Friday.

Leap Therapeutics, Inc. (LPTX) - Canvas Business Model: Revenue Streams

You're looking at the revenue generation side of Leap Therapeutics, Inc. (LPTX) as of late 2025, which is heavily weighted toward non-operational sources given its pre-commercial status and recent strategic pivot.

Zero Product Revenue

For the second quarter of 2025, Leap Therapeutics, Inc. reported $0.0 million in GAAP revenue. This aligns with its status as a clinical-stage biotechnology company without a commercialized product.

Interest Income

Minimal income is generated from the company's cash and cash equivalents. For the second quarter of 2025, the reported interest income amounted to $0.246 million.

Future Licensing/Milestone Payments

The primary potential revenue driver from its core biopharma assets centers on the DKN-01 asset. Leap Therapeutics, Inc. has an existing agreement with BeiGene, Ltd. for the development and commercialization of sirexatamab (DKN-01) in Asia (excluding Japan), Australia, and New Zealand. The company is eligible to receive payments from BeiGene based upon the achievement of certain development, regulatory, and sales milestones for a total deal value of up to $132 million, in addition to tiered royalties on product sales in the licensed territory. Management is actively exploring strategic alternatives, which could result in an asset sale or a new partnership structure.

• Potential future milestone/royalty payments from DKN-01 partnership: Up to $132 million total potential value from BeiGene, Ltd.
• The Board initiated a formal strategic alternatives process in Q2 2025.
• The company is prioritizing corporate development opportunities for sirexatamab (DKN-01) and FL-501.

Capital Gains: Digital Asset Holdings

Following a strategic shift and rebranding to Cypherpunk Technologies Inc. (ticker change to CYPH effective November 13, 2025), a significant portion of the company's treasury is now held in Zcash (ZEC) cryptocurrency. This strategy was funded by a private placement, with a portion of the proceeds used for accumulation. The potential for capital gains is tied directly to the appreciation of these digital assets.

Here's the quick math on the reported ZEC holdings as of mid-November 2025:

Metric	Value
Total ZEC Tokens Held (as of latest report)	232,644 tokens
Most Recent Purchase Amount	$18 million
Most Recent Tokens Acquired	29,869 ZEC
Average Price of Most Recent Purchase	$602.63 per token
Initial Private Placement Purchase Amount	$50 million
Initial Tokens Acquired	203,775.27 ZEC
Average Price of Initial Purchase	$245.37 per ZEC

The company's cash position, which funds near-term operations before any potential asset monetization, stood at $18.1 million on June 30, 2025.

Selected Financial Data (Q2 2025)

Financial Metric (GAAP)	Amount
GAAP Revenue	$0.0 million
Interest Income	$0.246 million
Cash and Cash Equivalents (End of Period)	$18.1 million
Net Loss	$16.6 million
Operating Cash Outflows	$14.486 million

Finance: draft 13-week cash view by Friday.